Inborn errors of metabolism:
Indications for: ELELYSO
Long-term enzyme replacement therapy (ERT) for patients with confirmed Type 1 Gaucher disease.
Adults and Children:
<4yrs: not established. Give by IV infusion over 60–120 minutes. ≥4yrs: 60 Units/kg once every 2 weeks. Begin treatment with Elelyso at the same dose when switching from imiglucerase.
ELELYSO Warnings/Precautions:
Have appropriate medical support available. Closely monitor patients during and after the infusion. Discontinue if anaphylaxis occurs and treat appropriately. Reduce or temporarily interrupt infusion, or administer antihistamines, corticosteroids and/or antipyretics if hypersensitivity reactions occur. Monitor for development of anti-drug antibodies. Pregnancy. Nursing mothers.
ELELYSO Classification:
Lysosomal glucocerebroside-specific enzyme.
Adverse Reactions:
Headache, arthralgia, fatigue, nausea, dizziness, abdominal pain, pruritus, flushing, vomiting, urticaria, extremity pain.
Generic Drug Availability:
NO
How Supplied:
Single-use vial—1
